Article

Provider portal offers 60-second benefit verification

Provider portal features an updated enrollment form, and potential for a 60-second benefit verification. 

Regeneron Pharmaceuticals is now offering EYLEA4U Connect, featuring an updated enrollment form, and potential for a 60-second benefit verification.

According to the company, an EYLEA4U Connect enrollment can help more than 40% of patients receive a benefit verification within 60 seconds for a faster time to treatment, and a better patient experience.

The company noted in a press release that EYLEA4U “will provide either a full benefit verification or notification that manual processing is required.”

Manual processing could take up to 48 hours, according to the press release.

Patient support

Regeneron’s EYLEA4U provides patient support for Eylea injections. The Eylea (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.

For patients with commercial insurance not funded through the U.S. government, EYLEA4U may offset some out-of-pocket co-pay costs.

Patients with insurance through a government healthcare program such as Medicare or Medicare Advantage can be referred to an independent charitable foundation designed to help patients pay for medications. An EYLEA4U specialist will not only refer patients to a charitable foundation, they will follow up with the foundation until a decision is made on the application.

For patients without insurance or whose insurance does not cover Eylea injections, EYLEA4U may be able to provide the drug free of charge. Regeneron also offers patients the EYLEA Injection Co-Pay Card Program.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.